Collaborative for the Economics of Psychedelics (CEP)
CEP is a network of health economists dedicated to achieving the potential of psychedelic therapies for high-priority mental health conditions.
Our Mission
Through the application of policy-relevant economic analyses, CEP seeks to enhance clinical outcomes, increase efficiency of service delivery, and increase access to these promising therapies for everyone who can benefit. Below is a list of current projects. This two-page summary provides additional information on CEP’s mission and activities.
What We’ve Achieved
In collaboration with the Usona Institute, modeling the cost-effectiveness of psilocybin-assisted psychotherapy to treat major depressive disorders.
In collaboration with the Multidisciplinary Association for Psychedelic Studies (MAPS), evaluating the cost-effectiveness of MDMA-assisted therapy for people with chronic PTSD.
Advisory Council
Rick Doblin, Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS)
Tura Patterson, Senior Director, Strategic partnerships, Usona Institute
Matthew Johnson, Associate Center Director, Johns Hopkins University, Center for Psychedelics & Consciousness Research
Eduardo Schenberg, Founder, Instituto Phaneros (São Paolo, Brazil)
In collaboration with Johns Hopkins University’s Center for Psychedelic and Consciousness Research, evaluating the cost-effectiveness of psilocybin-assisted therapy for smoking cessation.
In collaboration with MAPS and MAPS’ European partners, planning for the economic analyses that will be needed for the approval of MDMA-Assisted Therapy to treat PTSD in the UK and the EU.
